ArticleClinical and translational medicine2024
RETRACTION: The Novel Role of Circular RNA ST3GAL6 on Blocking Gastric Cancer Malignant Behaviours Through Autophagy Regulated by the FOXP2/MET/Mtor Axis.
Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between platelet-to-high-density lipoprotein cholesterol ratio and future stroke risk: a national cohort study based on CHARLS.Frontiers in neurology · 2024Article
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionP. Xu, X. Zhang, J. Cao, J. Yang, Z. Chen, W. Wang, S. Wang, L. Zhang, L. Xie, L. Fang, Y. Xia, Z. Xuan, J. Lv, H. Xu, and Z. Xu, "The Novel Role of Circular RNA ST3GAL6 on Blocking Gastric Cancer Malignant Behaviours Through Autophagy Regulated by the FOXP2/MET/Mtor Axis," Clinical and Translational Medicine 12, no.1 (2022): e707, https://doi.org/10.1002/ctm2.707. The above article, published online on 21 January 2022 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Xiangdong Wang; the Shanghai Institute of Clinical Bioinformatics; and John Wiley & Sons Australia, Ltd. The retraction has been agreed upon following an investigation into concerns raised by a third party, which revealed inappropriate duplications of image panels within the article (Figures 6H and 7J) and between this article (Figures 2D, 7B, 7K, 8E and 8J) and another article previously published elsewhere by an overlapping group of authors in a different scientific context. The authors were unable to provide a satisfactory explanation and the raw data they supplied could not explain the identified issues. In addition, the cell line SGC-7901 used in this study has been reported as contaminated with HeLa cells, making it a problematic model for gastric cancer [1,2]. Given the extent of the identified issues, the editors have lost confidence in the data presented and the article's conclusions can no longer be considered reliable. References [1] F. Ye, C. Chen, J. Qin, J. Liu, and C. Zheng, "Genetic Profiling Reveals an Alarming Rate of Cross-Contamination Among Human Cell Lines Used in China," The FASEB Journal 29, no. 10 (2015):4268-4272, https://doi.org/10.1096/fj.14-266718. [2] X. Bian, Z. Yang, H. Feng, H. Sun, and Y. Liu, "A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines," Scientific Reports 7, no. 1 (2017):9774, https://doi.org/10.1038/s41598-017-09660-w.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.